Zealand Pharma (CPSE:ZEAL) Stock Can Obesity Progress Outrun Milestone Driven Earnings?
Zealand Pharma stock came into today on a strong run, up 22% over the past month and 10% over three months, with investors leaning into its low 3.7x P/E and fresh profitability…
TR
By Tom Reyes · Markets Editor
Aug 14 03:00 ETSource: Simply Wall Street
From the source
Read at simplywall.stZealand Pharma (CPSE:ZEAL) Stock Can Obesity Progress Outrun Milestone Driven Earnings?
Zealand Pharma stock came into today on a strong run, up 22% over the past month and 10% over three months, with investors leaning into its low 3.7x P/E and fresh profitability over the last year. The earnings release keeps that tension front and center. H1 revenue landed at DKK 4.5b, powered by a DKK 3.7b Phase III milestone and a DKK 798m payment from Roche, and management highlighted DKK 14.5b
